PEER-REVIEWED · ANNALS OF ONCOLOGY · 2025

→

LUCC Lung: Europe's Largest Structured Lung Cancer Cohort

A curated, longitudinal dataset of 30,000 patients across 25 centers, covering all histologies, biomarker profiles, and treatment lines extracted by clinical AI from routine care documents, updated daily.

REQUEST A FEASIBILITY ASSESSMENT

30,000

Patients included

Centers

Real-World Studies

Dec 2023

Launch date

A living data layer for lung cancer research.
Evidence takes years to produce. Clinical practice changes in a matter of months. LUCC Lung updates a research-grade dataset every single day, so new therapies reach patients sooner.

data

Continuously updated

Longitudinal data points are updated daily. This is not a point-in-time snapshot.

TRACEABILITY

Source-linked

Every variable is traced back to its original clinical document.

PRIVACY

GDPR-compliant

Privacy by design. Pseudonymization at the point of care.

INFRASTRUCTURE

ISO 27001 · HDS

Certified secure hosting for health data.

METHODOLOGY

Listed by HAS

Cited by France's National Authority for Health as a real-world data source for health product assessments.

Guided by leading thoracic oncologists

Every study in the LUCC Lung program is designed and reviewed by an independent scientific committee of 9 experts from leading cancer and respiratory medicine centers.

SEC Chair - LUCC Lung

Prof. Benjamin Besse

Head of Clinical Research, Gustave Roussy Institute · Professor of Oncology, Paris-Saclay University

H-INDEX: 111 · 69,000+ CITATIONS · GOOGLE SCHOLAR

Dr. Hubert Curcio

Medical oncologist,
François Baclesse Center

Dr. Elvire Pons-Tostivint

Thoracic oncologist,
Nantes University Hospital

Prof. Emmanuel Bergot

Early-phase oncology
Bergonié Cancer Center, Bordeaux

Prof. Jaafar Bennouna

Head of Medical Oncology,
-Foch Hospital

Dr. Virginie Levrat

Pulmonologist,
, La Rochelle Hospital

Dr. Nicolas Cloarec

Head of Thoracic Oncology,
Avignon Hospital

Dr. Nicolas Rezvoy

Radiation Oncologist
, La Louvière Private Hospital

Laure Guéroult-Accolas

Founder & Managing Director,
Patients in Network (patient advocacy)

Franck Le Ouay

Co-founder & CEO,
Lifen

New member TBD

This is some text inside a div block.

LUCC Lung at a Glance

Longitudinal clinical data organized by clinical AI from routine care records, updated daily.

Cohort Growth

Cumulative total of patients, centers, and countries

H2 '23

H1 '24

H2 '24

12K

H1 '25

17K

H2 '25

25K

H1 '26

TARGET

40K

2027–28

Centers

Countries

🇫🇷

🇧🇪

🇪🇸 🇩🇪

H2 '23

X centers · 🇫🇷

H1 '24

X centers

H2 '24

X centers

H1 '25

12K

X centers

H2 '25

17K

X centers

H1 '26

25K

25 centers · + 🇧🇪

2027–28

40K

TARGET · 35 locations · + 🇪🇸 🇩🇪

Figures through the first half of 2026 are actuals. The figures for 2027–28 reflect the network expansion roadmap: Germany and Spain.

The largest structured hospital network for lung cancer in France

Centers

Type

Sites

Academic Medical Centers

University hospitals (CHU) & cancer centers (CLCC)

Community Centers

Community, private, and nonprofit hospitals

Total

Community hospital

Cancer Center (CLCC)

Nonprofit hospital

University Hospital (CHU)

Private hospital

Actionable biomarkers

Patients with detected abnormalities

1,914

KRAS

1,396

EGFR

410

ALK

308

BRAF

266

MET

210

PIK3CA

HER2

ROS1

RET

NTRK

PD-L1

Treatment Modalities

This is a subset of treatments provided for illustrative purposes only.

PD-1/PD-L1 inhibitors

Pembrolizumab · Durvalumab · Nivolumab · Atezolizumab

5,217

EGFR TKIs

Osimertinib · Erlotinib · Gefitinib · Lazertinib

1,092

ALK TKIs

Crizotinib · Alectinib · Lorlatinib · Brigatinib

844

Anti-VEGF

Bevacizumab

628

KRAS G12C inhibitors

Sotorasib · Adagrasib

193

CTLA-4

Ipilimumab

121

RET inhibitors

Selpercatinib · Pralsetinib

BRAF / MEK

Dabrafenib · Trametinib

25,696 treatment records across the cohort.

Request a detailed breakdown for your molecule →

Data Dictionary

Clinical variables extracted from unstructured medical documents. Additional variables are available upon request to meet study-specific needs.

Studies Currently Underway on LUCC Lung

Research questions answered using the LUCC Lung Research cohort.

Featured Study

EGFR-Predict

ANALYSIS IN PROGRESS

Can a predictive score help personalize the choice between osimertinib alone and osimertinib plus chemotherapy in patients with EGFR-mutated NSCLC?

292

patients

Centers

Dr. Nadia Guezour

Principal Investigator, Paris Saint-Joseph Hospital Group

INVESTIGATOR-INITIATED STUDIES

All have been approved by the Scientific Evaluation Committee.

Study

Research question & principal investigator

PDL1-HIGH

Descriptive and survival analysis of NSCLC patients with PD-L1 expression ≥50% treated with first-line chemo-immunotherapy.

Dr. Nuccio, Gustave Roussy

ICARE

The Value of Targeted Radiotherapy for Brain Metastases in Asymptomatic Patients Without Actionable Molecular Alterations.

Dr. Helissey, Paris Saint-Joseph Hospital Group

YOUNG40

Tumor characteristics and care pathway for patients diagnosed before age 40.

Dr. Colamartini / Dr. Aldea, Gustave Roussy

Apex

Care pathway for patients with Pancoast-Tobias syndrome.

Dr. Pons-Tostivint, Nantes University Hospital

BRAFVISION

Clinical Characteristics and Treatment Outcomes of BRAF V600E Non-Small Cell Lung Cancer.

Prof. Bennouna, Foch Hospital

RepliCate

Compare real-world outcomes in LUCC with those of reference clinical trial populations.

Dr. Aldea, Gustave Roussy

INDUSTRY-SPONSORED STUDIES

Sponsor names are disclosed upon publication.

Study

Research question

ALK-IA

Real-world outcomes of first-line ALK TKIs in ALK-positive NSCLC.

ANALYSIS IN PROGRESS

MONARCH

EGFR patient care pathways linked to SNDS.

RESULTS ARE BEING PREPARED

RECOG-KRAS

KRAS G12C Treatment Patterns: A European Multicenter Study.

"Lifen organizes complex clinical data from real-world documents with remarkable accuracy. This cohort provides us with the scale and granularity we need to answer questions that clinical trials cannot."

Dr. Mihaela Aldea

Thoracic Oncologist, Gustave Roussy

Lorem Ipsum is simply a dummy text used in the printing and typesetting industry. Lorem Ipsum has been the industry's.

Author Name

Vice President of the Company

Lorem Ipsum is simply a dummy text used in the printing and typesetting industry. Lorem Ipsum has been the industry's.

Author Name

Vice President of the Company

Lorem Ipsum is simply a dummy text used in the printing and typesetting industry. Lorem Ipsum has been the industry's.

Author Name

Vice President of the Company

Annals of Oncology · December 2025

3.2 times fewer errors than manual abstraction

311 patients, 31 clinical variables, and 10 centers. Three structuring methods were compared directly.

4.4%

error rate of the method used in LUCC Lung

vs. 14.2% for manual data extraction

9,641

data points independently evaluated

311 patients × 31 clinical variables

31/31

variables where AI outperformed manual abstraction

across all 10 participating centers

Error Rate by Structuring Method

Percentage of the 9,641 data points that were incorrectly extracted · lower is better

Manual Abstraction

14.2%

AI extraction

7.0%

Hybrid (AI + targeted human review)

4.4%

LUCC Lung is structured using the hybrid method. AI-based extraction alone already outperformed manual abstraction for all 31 variables and across all 10 centers.

Read the study in *Annals of Oncology* →

Get Started with LUCC Lung

Pharma & Biotech

Access structured cohorts for real-world evidence (RWE) studies, treatment pattern analyses, and post-market surveillance.

Request a feasibility assessment

→

Hospitals & Centers

Join the network. Share your data, participate in multicenter studies, and gain scientific recognition while receiving fair compensation for your teams.

Become a partner center

→

Patients

Your data helps advance lung cancer research. Learn about your rights and the study protocol.

Patient Information

→

LUCC Lung: Europe's Largest Structured Lung Cancer Cohort

Guided by leading thoracic oncologists

LUCC Lung at a Glance

Cohort Growth

The largest structured hospital network for lung cancer in France

Actionable biomarkers

Treatment Modalities

Data Dictionary

Studies Currently Underway on LUCC Lung

3.2 times fewer errors than manual abstraction

Get Started with LUCC Lung

Frequently Asked Questions